Silo Pharma, Inc. (SILO) Stock Price & Analysis

Silo Pharma, Inc. (SILO) fell 0.85% to USD 4.47 as of July 25, 2026 at 10:42 UTC, according to Nexqual real-time market data.

SILO last closed at USD 4.51; the session ranged USD 4.2–4.55 on volume of 30,811 shares. Market capitalization is $5.04M, with a 52-week range of USD 3.32–15.15 (NCM). Source: Nexqual, July 25, 2026 at 10:42 UTC.

Key Statistics (as of July 25, 2026 at 10:42 UTC)

Technical Analysis (SILO)

Nexqual's technical model rates SILO "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:42 UTC.

Analyst Ratings (SILO)

Wall Street analysts rate SILO "None", per Nexqual as of July 25, 2026 at 10:42 UTC.

Earnings (SILO)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 10:42 UTC.

Financials & Fundamentals (SILO)

Source: Nexqual, July 25, 2026 at 10:42 UTC.

Financial Health Score (SILO)

Nexqual rates Silo Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:42 UTC.

Ownership (SILO)

Source: Nexqual, July 25, 2026 at 10:42 UTC.

Leadership (SILO)

Silo Pharma, Inc. is led by Eric Weisblum (age 55), Chairman, President & CEO, per Nexqual as of July 25, 2026 at 10:42 UTC.

Major Backers & Investors (SILO)

Notable institutional backers of Silo Pharma, Inc. include Fidelity, AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, according to Nexqual as of July 25, 2026 at 10:42 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 10:42 UTC.

From Silo Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   Fibromyalgia affects approximately 4 million U.S. adults (2% of the population).
• Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents.
• In addition, we have established business procedures designed to maintain the confidentiality of our proprietary information, including the use of confidentiality agreements with employees, independent contractors, consultants and entities with which we conduct business.   To date, the intellectual property owned and licensed by us includes 5 issued patents and 20 pending patent applications in 14 patent families in the U.S. and abroad.

Partnerships

• SPC-14 was developed under a sponsored research agreement with Columbia University See "Investigator-Sponsored Study Agreements between the Company and Vendors---Sponsored Research Agreement with Columbia University for the Study of Ketamine in Combination with Other Drugs for Treatment of Alzheimer's and Depression Disorders." We have exclusive global rights to develop and commercialize SPC-14, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.
• We are actively collaborating with Columbia University, holding exclusive global rights to develop and commercialize SPC-15, pursuant to and that certain exclusive license agreement entered into with Columbia on July 1, 2024.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:42 UTC. This page is informational and not investment advice.